However, these mainstream therapies face critical limitations including the rapid emergence of drug resistance, FKS1/FKS2 gene mutations reducing -1,3-glucan synthase affinity, Targeted enzyme (Erg11p) modification, overexpression of efflux pumps (CDR1, MDR1), and upregulation of the ergosterol pathway mediate azole resistance (Pristov and Ghannoum, 2019)
In fact, the study authors stated that the epithalamin-treated patient group exhibited significantly lower mortality, decelerated aging, and normalized levels of melatonin production and lipid metabolism, compared to the control group [8]
Vendor repackaging Many US-based research chemical vendors are not manufacturers
In CRISPR-engineered iPSC-derived microglia and neurons, plus primary autopsy microglia and brain tissue, SORL1 deletion triggered endoplasmic reticulum stress, interferon signaling, lipid-droplet accumulation, and impaired phagocytosis
Off-Label Prescribing Considerations Some healthcare providers are already discussing GLP-1 therapy with patients at high risk for both metabolic disease and dementia